We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Rectal administration of low-dose diclofenac does not reduce post-endoscopic retrograde cholangiopancreatography pancreatitis: a propensity score matching analysis.
- Authors
Sakai, Hiroaki; Iwai, Naoto; Sakagami, Junichi; Okuda, Takashi; Ohara, Tomoya; Hattori, Chie; Taniguchi, Masashi; Oka, Kohei; Hara, Tasuku; Tsuji, Toshifumi; Komaki, Toshiyuki; Kagawa, Keizo; Dohi, Osamu; Yasuda, Hiroaki; Konishi, Hideyuki; Itoh, Yoshito
- Abstract
Background: Endoscopic retrograde cholangiopancreatography (ERCP) is a popular technique; however, post-ERCP pancreatitis (PEP) remains a major adverse event. The administration of rectal nonsteroidal anti-inflammatory drugs (NSAIDs) is reportedly effective in preventing PEP. However, the recommended dose varies and the efficacy of low-dose rectal NSAIDs remains unclear. Therefore, we decided to investigate the effectiveness of low-dose rectal diclofenac on PEP prevention, using propensity score matching. Methods: This single-center retrospective study included 401 patients who underwent ERCP between July 2015 and March 2020. After December 2016, we administered rectal diclofenac within 30 min before the ERCP procedure as widely as possible. Patients were divided into those who did (diclofenac group) and did not (control group) receive rectal diclofenac. Patients weighing ≥ 50 kg were administered a 50 mg dose, while those weighing < 50 kg were administered a 25 mg dose. The incidence and severity of PEP in the two groups were assessed by propensity score matching analysis. Results: Among 401 patients undergoing ERCP, 367 fulfilled the inclusion criteria. Overall, 187 patients received rectal diclofenac (diclofenac group) and 180 did not (control group). After propensity score matching, 105 pairs were selected for evaluation. Overall, seven (6.7%) patients in the diclofenac group and 10 (9.5%) in the control group developed PEP (P = 0.45). Moderate or severe PEP occurred in four (3.8%) patients in the diclofenac group and six (5.7%) in the control group (P = 0.52). Conclusions: The administration of low-dose rectal diclofenac could not reduce the incidence and severity of PEP.
- Subjects
PROPENSITY score matching; RECTAL administration; DICLOFENAC; ENDOSCOPIC retrograde cholangiopancreatography; PANCREATITIS; ANTI-inflammatory agents
- Publication
Surgical Endoscopy & Other Interventional Techniques, 2023, Vol 37, Issue 4, p2698
- ISSN
1866-6817
- Publication type
Article
- DOI
10.1007/s00464-022-09718-5